SG11201500579SA - Modified factor x polypeptides and uses thereof - Google Patents

Modified factor x polypeptides and uses thereof

Info

Publication number
SG11201500579SA
SG11201500579SA SG11201500579SA SG11201500579SA SG11201500579SA SG 11201500579S A SG11201500579S A SG 11201500579SA SG 11201500579S A SG11201500579S A SG 11201500579SA SG 11201500579S A SG11201500579S A SG 11201500579SA SG 11201500579S A SG11201500579S A SG 11201500579SA
Authority
SG
Singapore
Prior art keywords
polypeptides
modified factor
factor
modified
Prior art date
Application number
SG11201500579SA
Other languages
English (en)
Inventor
Edwin L Madison
Christopher Thanos
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of SG11201500579SA publication Critical patent/SG11201500579SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201500579SA 2012-07-25 2013-03-15 Modified factor x polypeptides and uses thereof SG11201500579SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261741806P 2012-07-25 2012-07-25
PCT/US2013/032616 WO2014018120A1 (en) 2012-07-25 2013-03-15 Modified factor x polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
SG11201500579SA true SG11201500579SA (en) 2015-02-27

Family

ID=48040462

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500579SA SG11201500579SA (en) 2012-07-25 2013-03-15 Modified factor x polypeptides and uses thereof

Country Status (17)

Country Link
US (2) US9145552B2 (enrdf_load_stackoverflow)
EP (1) EP2877487B1 (enrdf_load_stackoverflow)
JP (2) JP6363600B2 (enrdf_load_stackoverflow)
KR (1) KR102049900B1 (enrdf_load_stackoverflow)
CN (1) CN104755492A (enrdf_load_stackoverflow)
AU (1) AU2013293573B2 (enrdf_load_stackoverflow)
BR (1) BR112015001628A2 (enrdf_load_stackoverflow)
CA (1) CA2879785C (enrdf_load_stackoverflow)
EA (1) EA028865B1 (enrdf_load_stackoverflow)
ES (1) ES2704083T3 (enrdf_load_stackoverflow)
IL (1) IL236449B (enrdf_load_stackoverflow)
IN (1) IN2015DN01404A (enrdf_load_stackoverflow)
MX (1) MX365612B (enrdf_load_stackoverflow)
NZ (1) NZ703148A (enrdf_load_stackoverflow)
SG (1) SG11201500579SA (enrdf_load_stackoverflow)
WO (1) WO2014018120A1 (enrdf_load_stackoverflow)
ZA (1) ZA201500097B (enrdf_load_stackoverflow)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735439B1 (en) 2004-04-12 2011-11-23 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US20070093443A1 (en) 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
EP2402438A3 (en) 2006-07-05 2012-03-28 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
DK2147096T3 (da) * 2007-04-13 2015-06-15 Catalyst Biosciences Inc Modificerede faktor-VII-polypeptider og anvendelser deraf
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
DK3096779T3 (da) * 2014-01-24 2020-02-24 Pfizer Sammensætninger og fremgangsmåder til behandling af intracerebral blødning
US10444715B2 (en) * 2014-05-01 2019-10-15 Belkin International, Inc. Controlling settings and attributes related to operation of devices in a network
US10537618B2 (en) 2014-05-26 2020-01-21 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
EP3242936A1 (en) * 2015-01-07 2017-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated factor x polypeptides and uses thereof for the treatment of haemophilia
WO2017017109A1 (en) * 2015-07-27 2017-02-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated factor x polypeptides and uses thereof for the treatment of haemophilia
EP3400029B1 (en) * 2016-01-07 2022-03-02 Eio Biomedical Ltd Compositions for reducing tissue adhesions
FR3050992A1 (fr) * 2016-05-06 2017-11-10 Lab Francais Du Fractionnement Mutants du facteur x
FR3077296A1 (fr) * 2018-02-01 2019-08-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Dimeres de variants du facteur x
WO2019201868A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Coagulation factor based fusion protein with half-life extending polypeptide
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
EP3831843A1 (en) * 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland A hemostatic agent and uses thereof
WO2023086388A1 (en) * 2021-11-09 2023-05-19 YewSavin, Inc. Compositions and methods for treating bleeding and bleeding disorders
CN115725594B (zh) * 2022-03-03 2024-11-08 南京医科大学 Pipiserpin蛋白在蚊媒种群控制中的应用
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116426510B (zh) * 2023-06-13 2023-09-22 北京沃森赛瑟生物技术有限公司 含修饰Xa因子的利伐沙班检测试剂盒及检测方法与应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
WO1998039456A1 (en) 1997-03-07 1998-09-11 Washington University Factor x variant
US20030207402A1 (en) 1997-08-22 2003-11-06 Erhard Kopetzki Autocatalytically activatable zymogenic precursors of proteases and their use
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
US20030186329A1 (en) 1999-03-22 2003-10-02 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2002230390A1 (en) 2000-10-05 2002-04-29 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
EP1545572A4 (en) 2001-05-23 2006-04-12 Dendreon Corp CELL SURFACE PROTEINS ACTIVATED CONJUGATES AND THERAPEUTIC USES THEREOF
WO2003004681A2 (en) 2001-07-03 2003-01-16 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
WO2003031585A2 (en) 2001-10-09 2003-04-17 Dendreon Corporation Transmembrane serine protease 25
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
WO2003044179A2 (en) 2001-11-20 2003-05-30 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003247776A1 (en) 2002-07-02 2004-01-23 Dendreon Corporation Serine protease 16
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
SG188669A1 (en) 2002-10-02 2013-04-30 Catalyst Biosciences Inc Method of generating and screening for proteases with altered specificity
WO2005022330A2 (en) 2003-08-27 2005-03-10 Jambo Networks, Inc. A system and method for providing communication services to mobile device users
WO2005023308A1 (en) 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
DE10350880A1 (de) 2003-10-31 2005-06-02 Roche Diagnostics Gmbh Verfahren zur Bestimmung eines Analyten mittels einer Extraktionsschicht
EP1735439B1 (en) 2004-04-12 2011-11-23 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
WO2005123119A2 (en) 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration of neutral endopeptidase to treat inflammatory bowel disease
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
EP1726643A1 (en) 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US20070093443A1 (en) 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
WO2007149406A2 (en) 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
EP2402438A3 (en) 2006-07-05 2012-03-28 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
DK2147096T3 (da) 2007-04-13 2015-06-15 Catalyst Biosciences Inc Modificerede faktor-VII-polypeptider og anvendelser deraf
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
DK2202306T3 (da) 2007-10-09 2013-01-21 Chemo Sero Therapeut Res Inst Rekombinant faktor x uden glycosylering og fremgangsmåde til fremstilling deraf
CN102014948A (zh) 2008-02-07 2011-04-13 安德鲁·贝克 腺病毒向性的调节
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
JP5665733B2 (ja) * 2008-04-21 2015-02-04 ノボ ノルディスク ヘルス ケア アーゲー 高度にグリコシル化されたヒト凝固第ｉｘ因子
HRP20181442T1 (hr) 2008-09-15 2018-12-14 Uniqure Biopharma B.V. Mutant polipeptida faktora ix, njegove koristi i postupak njegove proizvodnje
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
ES2629099T3 (es) 2008-12-19 2017-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de serin proteasa y usos en la prevención o el tratamiento de y trastornos de la coagulación sanguinea
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
CA2767858C (en) * 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP2760887B1 (en) 2011-09-30 2024-10-23 The Children's Hospital of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof

Also Published As

Publication number Publication date
ZA201500097B (en) 2016-09-28
JP2015524801A (ja) 2015-08-27
BR112015001628A2 (pt) 2017-11-07
US20140234290A1 (en) 2014-08-21
MX365612B (es) 2019-06-07
WO2014018120A1 (en) 2014-01-30
JP6363600B2 (ja) 2018-07-25
KR20160073937A (ko) 2016-06-27
IL236449A0 (en) 2015-02-26
KR102049900B1 (ko) 2019-11-28
IL236449B (en) 2019-02-28
US9145552B2 (en) 2015-09-29
HK1210790A1 (en) 2016-05-06
MX2015001083A (es) 2015-04-08
EP2877487B1 (en) 2018-10-17
EA201500172A1 (ru) 2015-09-30
EA028865B1 (ru) 2018-01-31
NZ703148A (en) 2016-08-26
AU2013293573B2 (en) 2016-10-27
AU2013293573A1 (en) 2015-02-05
CA2879785A1 (en) 2014-01-30
ES2704083T3 (es) 2019-03-14
US9856467B2 (en) 2018-01-02
US20140030247A1 (en) 2014-01-30
EP2877487A1 (en) 2015-06-03
CA2879785C (en) 2019-06-18
CN104755492A (zh) 2015-07-01
IN2015DN01404A (enrdf_load_stackoverflow) 2015-07-03
JP2018183147A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
IL261632B (en) Chimeric factor viii polypeptides and uses thereof
ZA201500097B (en) Modified factor x polypeptides and uses thereof
GB201201100D0 (en) Polypeptides and methods
IL254416A0 (en) Anti-asic1 antibodies and their uses
SG11201500111VA (en) Peptides and uses thereof
IL237926A0 (en) Combinations and their uses
SG11201501646PA (en) Peptides and their uses
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
SG11201402139UA (en) High mast2-affinity polypeptides and uses thereof
ZA201407276B (en) Polypeptides and their use
EP2820034A4 (en) MODIFIED ADIPONECTINPOLYPEPTIDES AND ITS USES
EP2907870A4 (en) REPROGRAMMING PEPTIDE AND USE THEREOF
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
ZA201504462B (en) TGFß-DERIVED POLYPEPTIDES AND USES THEREOF
GB201210303D0 (en) Polypeptides and methods
GB201214769D0 (en) Methodsa and peptides
GB201208372D0 (en) Antibodies and uses thereof